RecruitingPhase 2NCT06356155

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

Studying Upper tract urothelial carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Michigan Rogel Cancer Center
Principal Investigator
Irene Tsung, MD
University of Michigan
Intervention
Enfortumab vedotin(drug)
Enrollment
32 target
Eligibility
18 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06356155 on ClinicalTrials.gov

Other trials for Upper tract urothelial carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Upper tract urothelial carcinoma →

← Back to all trials